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Se´zary Syndrome
Leslie van der Fits1,4, Yongjun Qin1,4, Jacoba J. Out-Luiting1, Kim G. Vermeer1, Sean Whittaker2,
Johan H. van Es3, Cornelis P. Tensen1 and Maarten H. Vermeer1
NOTCH signaling is important for development and tissue homeostasis and is activated in many human cancers.
We investigated a role for NOTCH1 signaling in Se´zary syndrome (SS), a cutaneous T-cell lymphoma in which
CD4þ tumor cells (Se´zary cells) are present in the skin, lymph nodes, and peripheral blood. We show
consistent expression of activated NOTCH1 by Se´zary cells isolated from peripheral blood of SS patients, as well
as the SS-derived cell lines SeAx and HuT78. In addition, immunohistochemical stainings of skin biopsies from
SS patients showed consistent expression of nuclear NOTCH1 and its downstream target hairy/enhancer of
split-1 (HES1) by Se´zary cells. We demonstrate that this persistent NOTCH1 activation is not caused by
mutations in the coding regions of NOTCH1 and F-box and WD40 domain protein 7 (FBWX7) genes. Inhibition
of NOTCH1 signaling by gamma secretase inhibitors decreased cellular viability and induced apoptosis of
Se´zary cells. These observations argue that NOTCH1 signaling is functionally involved in the pathogenesis of SS,
and inhibition of NOTCH1 signaling represents a new therapeutic target for the treatment of SS.
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INTRODUCTION
Se´zary syndrome (SS) is an aggressive lymphoma/leukemia of
skin-homing, CD4þ memory T cells characterized by the
presence of neoplastic T cells (SS cells) in the skin, lymph
nodes, and peripheral blood. Although SS can be treated with
low-dose prednisone and chlorambucil or immunomodulat-
ing therapies (extracorporeal photophoresis, IFN-a), the
prognosis is poor, with a median survival between 2 and 4
years after diagnosis and a disease-specific 5-year survival
around 20%. New treatments are being developed for SS,
including histone deacetylase inhibitor and allogenic stem
cell transplantation. However, these treatments are asso-
ciated with significant acute and long-term toxicities, and
therefore identification of new therapeutic targets remains an
urgent medical need (Olsen et al., 2011).
Activated NOTCH1 signaling has been implicated in the
tumorigenesis of a growing list of hematologic malignancies
including T-cell acute lymphoblastic leukemia (T-ALL),
Hodgkins disease, anaplastic large-cell lymphoma, and
chronic lymphocytic leukemia (Ellisen et al. 1991; Jundt
et al., 2002; Weng et al., 2004; Asnafi et al., 2009; Rosati
et al., 2009; Fabbri et al., 2011). NOTCH proteins are single-
pass transmembrane receptors noncovalently joined as
heterodimers through a structural motif termed the hetero-
dimerization domain (HD). In humans, four NOTCH homo-
logs are known (NOTCH1-4) and two families of NOTCH
ligands have been identified, the Jagged/Serate-like ligands
(Jagged1 and Jagged2) and the Delta-like ligands (DLL1,
DLL3, and DLL4). On ligand binding, NOTCH1 undergoes
multiple proteolytic cleavages that will allow the intracellular
domain of NOTCH (icNOTCH) to translocate to the nucleus.
Nuclear icNOTCH associates with the DNA-binding factor
CBF1-suppressor of hairless-Lag1, leading to recruitment of the
scaffolding proteins of the Mastermind-like family and other
cofactors, resulting in transactivation of target genes such as the
transcriptional repressor hairy/enhancer of split (HES) (Oellers
et al., 1994; Heitzler et al., 1996), c-MYC, CD28, and the
NOTCH receptors themselves. The F-box and WD40 domain
protein 7 (FBXW7) acts as a negative regulator of NOTCH
signaling by binding to the phosphatase and tensin homolog
(PEST) domain in the C terminus of icNOTCH, thereby marking
activated NOTCH for ubiquitinylation and proteosomal
degradation (Fryer et al., 2004; Tetzlaff et al., 2004).
A role for the NOTCH1 gene in human leukemogenesis
was originally recognized through identification of chromo-
somal translocation (7;9)(q34;q34.3) in T-ALL (Ellisen et al.
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1991). This translocation results in the juxtaposition of the
30region of NOTCH1 into the TCR-b locus and constitutive
expression of activated icNOTCH. In addition, over 50% of
T-ALL harbor mutations in NOTCH1, either in the HD region
leading to ligand-independent NOTCH1 activation or in the
PEST domain resulting in deletion of the recognition site for
proteosomal degradation by the FBXW7/stem cell factor
complex (Weng et al., 2004; Asnafi et al., 2009). In addition
to these mutations in the NOTCH1 gene, about 15% of T-ALL
contain mutations in FBXW7 that impair substrate recogni-
tion by the FBXW7/stem cell factor complex and impair the
degradation of activated icNOTCH1 (O’Neil et al., 2007;
Thompson et al., 2007). In 20% of T-ALL cases, the tumor-
suppressor phosphatase and tensin homolog (PTEN) gene is
mutated or lost, which has been suggested to be a critical
event leading to resistance to NOTCH inhibition (Palomero
et al., 2007; Medyouf et al., 2010).
Recently, expression of NOTCH1 protein by SS cells was
described in two of five skin biopsies and one peripheral
blood sample from SS patients (Kamstrup et al., 2010). These
observations prompted us to investigate the expression of
NOTCH1 and hairy/enhancer of split-1 (HES1), evaluate
underlying mutations, and explore the potential therapeutic
effect of inhibition of NOTCH1 signaling in SS.
RESULTS
Se´zary cells express activated NOTCH1 and HES1
We performed immunohistochemical studies on skin biopsies
from 12 SS patients (Figure 1) using an antibody specific for
the N-terminal sequence of icNOTCH1. In all 12 cases,
nuclear localization of icNOTCH1 was detected in 80 to
100% of neoplastic cells, consistent with active NOTCH1
signaling (Figure 1d and e). In addition, intra-epidermal
collections of neoplastic cells (Pautrier micro-absesses)
stained positive for icNOTCH1 (Figure 1g). In line with the
observed expression of activated NOTCH1, we found strong
nuclear expression of the downstream NOTCH1 target gene
HES1, the prototype human HES gene, in 80 to 100% of
neoplastic cells in all SS biopsies (Figure 1f and h). Skin
biopsies from psoriasis (n¼ 4) and atopic dermatitis (n¼ 4)
showed weak nuclear staining of infiltrating T cells for
icNOTCH1 in 80 to 100% and HES1 in 70 to 100% (Figure 1i
and j). Expression of NOTCH1 by keratinocytes in the stratum
basale and stratum spinosum served as an internal control
(Nickoloff et al., 2002).
Flow cytometric analysis was performed on SS cells
isolated from the peripheral blood of seven SS patients using
an antibody that specifically recognizes the cleaved intracel-
lular part of NOTCH1, and possesses low affinity for the full-
length NOTCH1. In SS cell line SeAx, a sub-population of
cells was negative for icNOTCH1, whereas the majority of
cells stained positive; however, all HuT78 cells were positive
(Figure 2a). In primary SS cells isolated from all patients,
consistent increased staining was detected with the ic-
NOTCH1 antibody, when compared with the isotype control
(Figure 2b, P¼0.012, Wilcoxon test). In addition, flow
cytometric analysis of CD4þ cells from the peripheral blood
from patients with psoriasis (n¼2) and eczema (n¼ 4) was
performed. These cells also stain positive for icNOTCH1,
which is in agreement with results presented in Figure 1, as
well as with recent literature that showed NOTCH1 activa-
tion on stimulation of mature T cells (Koyanagi et al. 2012).
The amount of icNOTCH1 expression, depicted as median
fluorescence intensity relative to the isotype control, was not
significantly different between patients with SS, psoriasis, and
eczema (Figure 2c).
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Figure 1. Se´zary cells demonstrate nuclear expression of NOTCH1 and
hairy/enhancer of split 1 (HES1). Two representative examples of paraffin-
embedded skin biopsies from Se´zary patients (n¼12) showing dermal
infiltration of large atypical T cells in hematoxylin and eosin (H&E) staining (a)
that express CD4 (b) but are negative for CD8 (c). The majority of atypical T
cells show nuclear expression of NOTCH1 (d, e, g) and HES1 (f, h). In
addition, infiltrating lymphocytes in psoriatic skin stain positive for NOTCH1
(i) and HES1 (j). The depicted scale bars represent 200mm (a, b, c, i, j), 400 mm
(d), and 100 mm (e, f, g, h).
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Se´zary cells do not contain mutations in NOTCH1, FBXW7, and
PTEN genes
Aberrant activation of NOTCH1 in T-ALL has been attributed
to mutations in the HD domain and PEST domain of the
NOTCH1 gene, or to mutations in FBXW7 that impair
ubiquitinization and proteosomal degradation of NOTCH1
protein. To assay whether these type of mutations underlie
the activated NOTCH1 signaling that is observed in SS, we
performed sequence analysis of the HD region (exon 26) and
PEST region (exon 34) of the NOTCH1 gene and the entire
coding region of the FBXW7 gene on genomic and comple-
mentary DNA of 10 SS patients. We found no mutations in
FBXW7 and no activating mutation in the HD and PEST
region of the NOTCH1 gene. Mutation analysis of the entire
coding region of PTEN was performed on genomic com-
plementary DNA of 10 SS patients as well, because it has
been reported that mutations in PTEN can lead to resistance
to NOTCH1 inhibition. However, none of these 10 patients
showed any mutation in PTEN. Careful examination of
previously obtained array-based comparative genome hybri-
dization data available for six of these SS patients (Vermeer
et al., 2008) showed amplification of FBXW7 in one of six
patients and heterozygous deletion of PTEN in four of six
patients (Supplementary Table S1 online). Copy number
alterations for theNOTCH1 gene could not be assayed, as the
NOTCH1-encoding region was not covered by BAC clones
on the array.
GSI-I and GSI-XXI induce apoptosis in Se´zary cells
We assayed the effects of inhibition of NOTCH signaling on
the survival and apoptosis of SS cells, by treating SS cells with
g-secretase inhibitors (GSI)-I and GSI-XXI. Incubation of SeAx
cells with GSI-I resulted in a consistent decrease in
icNOTCH1, whereas the effects of GSI-XXI were less
consistent (Figure 3a and b).
Treatment of primary SS cells with high doses of GSI-XXI
(X5 mM) for 72 hours resulted in marginally decreased
numbers of viable cells in four of six Se´zary patients, whereas
no decrease in the number of viable SS cells was observed in
two patients (Figure 3c), as well as for SeAx and HuT78 cell
lines (data not shown).
In contrast, incubation of freshly isolated CD4þ SS cells
with GSI-I (0.5–5 mM) for 72 hours led to a dose-dependent
decrease in cell viability for all patients tested (n¼3,
P¼0.034, Mann–Whitney test) (Figure 3b), as well as for
SeAx and HuT78 cell lines (data not shown).
We further examined whether this reduced number of
viable cells after NOTCH inhibition is due to the induction of
apoptosis. Freshly isolated CD4þ T cells from three Se´zary
patients were incubated with 5mM GSI-I for 16 to 24 hours,
and flow cytometric analysis was performed with Annexin-V
and propidium iodide staining. A low percentage of apoptotic
cells were detected after culturing in medium alone (1–3%),
and this percentage did not change on addition with a
volume equivalent of DMSO. However, after incubation with
5 mM GSI-I, the number of apoptotic cells was significantly
increased to 5–15%. In addition, the number of dead
cells increased on GSI-I induction (Figure 4, P¼0.034,
Mann–Whitney test).
NOTCH1 signaling does not potentiate STAT3 signaling in SS
Previous studies showed that the NOTCH1 target gene HES1
can facilitate JAK2/signal transducer and activator of tran-
scription (STAT)-3 complex formation and promote STAT3
phosphorylation and activation (Kamakura et al., 2004). As a
functional role for activated STAT3 signaling in SS has been
demonstrated previously (Eriksen et al., 2001; van Kester
et al., 2008), we assessed whether cross talk between
NOTCH1 and STAT3 signaling is operative in SS. NOTCH1
signaling was activated in freshly isolated SS cells and SeAx
cells by incubation with NOTCH1 ligand (JAG1 peptide) for
various time points. Incubation of SeAx cells with JAG1
peptide resulted in a slight but consistent increase in
icNOTCH1 expression, demonstrating the effectiveness of the
peptide (Figure 5a and b). In contrast, JAG1 peptide did not
have any effect on activation of STAT3, as assessed by flow
cytometry using an antibody recognizing phosphorylated
STAT3 (Figure 5c). In addition, pre-incubation of freshly
isolated SS cells or SeAx cells with JAG1 peptide for 16 hours
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Figure 2. Se´zary cells express activated NOTCH1. icNOTCH1 expression
was assayed by flow cytometry in Se´zary syndrome (SS) cell lines SeAx and
HuT78 (a), and in CD4þ T cells isolated from peripheral blood of SS patients
(n¼7; two representative examples are shown, b). Cells remained unstained
(filled graph), or were stained using a phycoerythrin (PE)-conjugated isotype
control antibody (dashed line) or a PE-conjugated antibody recognizing the
intracellular part of NOTCH1 (solid line). The median fluorescent intensity,
relative to the isotype control, was calculated for CD4þ cells from seven SS
patients, two psoriasis patients (Psor), and four patients with atopic dermatitis
(Ecz) (c).
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did not lead to potentiation or elongation of the STAT3
response after subsequent stimulation of these cells with IL-
21, a known activator of STAT3 signaling (Figure 5d).
DISCUSSION
In this paper, we demonstrate that NOTCH1 signaling and
expression of HES1, a canonical NOTCH1 target gene, is
consistently found in the large majority of SS cells in
peripheral blood and skin. We found that the activated
NOTCH1 signaling does not result from NOTCH1 or FBWX7
mutations and show that inhibition of NOTCH1 signaling
results in apoptosis of Se´zary cells. These results suggest that
NOTCH1 signaling is a promising therapeutic target in SS.
In this study, staining studies of skin biopsies from SS
patients using an antibody specific for the N-terminal
sequence of icNOTCH1 showed nuclear staining in the
majority of tumor cells in all cases. In line with this finding,
FACS analysis of peripheral blood from SS patients demon-
strated consistent expression of icNOTCH1 in the majority of
tumor cells. Analysis of skin biopsies and peripheral blood
from psoriasis and atopic eczema patients showed expression
of icNOTCH1 and HES1 by the majority of reactive cells as
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Figure 3. Inhibition of Notch signaling by the c-secretase inhibitors (GSI)-I
and GSI-XXI leads to reduced viability of Se´zary cells. SeAx cells were
treated with GSI-I or GSI-XXI, and intracellular domain of NOTCH1
(icNOTCH1) expression was assayed by flow cytometry. A representative
example of a flow cytometric experiment is shown (a). The percentage of
icNOTCH-positive cells was calculated relative to the percentage in DMSO-
treated cells for each individual experiment (3 hours, n¼ 2; 6 hours, n¼3),
and is depicted in panel b. Freshly isolated Se´zary cells were incubated with
10mM GSI-XXI (c) or GSI-I at the concentration indicated (d). Cell viability was
assayed after 72 hours using a WST test. Bars represent the percentage of
viable cells, relative to the number of nontreated cells. A representative
example of three patients is shown in panel b.
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Figure 4. Inhibition of Notch1 signaling by the c-secretase inhibitor (GSI)-I
in Se´zary cells results in increased apoptosis. Freshly isolated CD4þ T cells
of three different Se´zary syndrome (SS) patients were cultured with or without
5mM GSI-I or with a volume equivalent of DMSO for 16 to 24 hours. Cells
were subjected to propidium/Annexin-V labeling, and apoptotic cells were
quantified by flow cytometric analysis. The number of dead, living, and
apoptotic cells was calculated as percentage of the total number of cells. Bars
denote mean±SD of duplicate measurements.
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well. These results are in line with a recent publication
demonstrating the rapidly increased expression of NOTCH1
and NOTCH3 in mature T cells on activation (Koyanagi et al.,
2012). A previous study using a different antibody directed
against full-length and truncated NOTCH1 showed mainly
cytoplasmic and occasionally nuclear staining of NOTCH1 in
two of five skin biopsies (Kamstrup et al., 2010). The more
homogeneous expression pattern of icNOTCH1 described by
us compared with these previous findings most probably
results from differences in staining characteristics of the
antibodies that were used in the different studies. The
consistent expression of icNOTCH1 found in the large
majority of SS cells in skin, as well as peripheral blood
detected in this study, strongly suggests that activated
NOTCH1 signaling is operative in SS cells.
Various mechanisms can attribute to constitutive
NOTCH1 signaling in tumor cells, including translocation
and mutation of the NOTCH1 gene. We show that in SS no
mutations are present in the HD and PEST domains of the
NOTCH1 and FBXW7 gene, indicating that other regulatory
mechanisms are operative in SS.
Alternative explanations for increased NOTCH1 signaling
in cancers that do not contain NOTCH1 mutations include
decreased expression of miR-200 members that target
NOTCH pathway components (Brabletz et al., 2011), high
expression of Mastermind-like 2 (Ko¨chert et al., 2011), and
deletion of the 50 NOTCH1 promoter that allows generation
of leukemogenic NOTCH1 protein from cryptic internal
promoters in this region (Gomez del Arco et al., 2010). In
addition, studies in Hodgkin and anaplastic large-cell
lymphoma showed Jagged1 expression in malignant and
bystander cells colocalizing with NOTCH1-positive tumor
cells, suggesting that NOTCH1 signaling may be activated
through homotypic or heterotypic cell–cell interactions (Jundt
et al., 2002). If similar or yet other mechanisms are
responsible for NOTCH1 expression in SS is clearly of
interest.
Studies in human T-ALL cell lines reported that loss of
PTEN correlates with resistance to NOTCH inhibition and
loss of PTEN accelerated disease onset in a murine T-ALL
model (Palomero et al., 2007; Medyouf et al., 2010). These
observations raised the concern that therapeutic intervention
inhibiting NOTCH signaling will be less effective in PTEN
insufficient tumors. We did not detect PTEN mutations in the
patients included in this study, but examination of previously
published array-based comparative genome hybridization
data of a subset of patients included in this study identified a
heterozygous deletion of PTEN in four of six SS patients.
Whether the loss of one PTEN allele leads to resistance to
inhibition of NOTCH1 signaling in SS is currently unknown
and should be addressed in future studies.
Important direct target genes of NOTCH1 signaling
include c-MYC and HES1. In line with the activated
NOTCH1 signaling, we found consistent expression of
HES1 protein by the majority of SS cells. In T-ALL, NOTCH1
signaling induces expression of HES1 that downregulates the
deubiquitinase CYLD, a negative IKB kinase complex
regulator, leading to sustained NF-kB activation (Espinosa
et al., 2010; D’Altri et al., 2011). In line with these findings,
studies in SeAx cell line showed that downregulation of
NOTCH1 resulted in downregulation of NF-kB in these cells
as well (Kamstrup et al., 2010). On the basis of these findings,
it will be of interest to investigate whether NOTCH1-induced
HES1 protein has a role in the nuclear expression of NF-kB
that was reported in SS patients (Sors et al., 2006).
Gene expression studies and chromatin immune precipi-
tation (ChIP) analysis showed that c-MYC is a direct target of
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Figure 5. Stimulation of NOTCH signaling does not influence signal
transducer and activator of transcription (STAT)-3 activation in Se´zary
syndrome (SS) cells. SeAx cell were incubated for the indicated time points
with 40 mM JAG1 peptide, and intracellular domain of NOTCH1 (icNOTCH1)
expression was determined by flow cytometry to assay the effectiveness of
the peptide preparation. A representative example is shown in panel a. In
addition, the percentage of icNOTCH-positive cells was calculated relative to
the percentage in DMSO-treated cells for each individual experiment (n¼ 3),
and is depicted in panel b. Freshly isolated CD4þ T cells from an SS patient
were stimulated with 40mM JAG1 peptide for the indicated time points (c), or
overnight, and subsequently activated by IL-21 for various time points (d).
STAT3 activation was assayed by flow cytometric analysis using an antibody
specifically recognizing phosphorylated STAT3, and is depicted as mean
fluorescent intensity (MFI) of duplicated measurements (mean±SD).
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NOTCH1, and ‘‘ChIP on ChIP’’ analysis revealed that c-MYC
and NOTCH1 share common targets regulating growth,
metabolism, and proliferation (Palomero et al., 2006; Weng
et al., 2006). As a high proportion of SS cells contain copy
number alterations leading to increased expression of c-MYC
(Vermeer et al., 2008), it will be of interest to investigate
whether NOTCH1 and c-MYC are involved in a feed-forward
loop that reinforces the expression of genes required for
growth and proliferation in SS. Moreover, NOTCH1 signaling
can induce resistance to apoptosis in T cells by upregulating
the expression of inhibitor of apoptosis, B-cell lymphoma 2
(BCL-2), and FLICE-like inhibitor protein (Sade et al., 2004).
Given the resistance to apoptosis and expression of
FLICE-like inhibitor protein typically observed in SS cells, it
will be of interest to investigate whether these genes
are regulated by NOTCH signaling in SS as well (Contassot
et al., 2008).
Among the STAT3 target genes that were described
previously, several gene targets including the cell–cycle
regulators (e.g., CYCLIN-D1 and c-MYC) and inhibitors of
apoptosis (BCL2) are shared with NOTCH1. Recent studies
demonstrated in mouse neuroepithelial cells and HeLa cervix
cancer cell line showed that NOTCH1-induced expression of
HES-1 proteins can associate with JAK2 and STAT3, thereby
facilitating JAK2/STAT3 complex formation and promoting
STAT3 phosphorylation and activation (Kamakura et al., 2004;
Lee et al., 2009). As understanding of these interactions
enhances the ability to design rational combination regimens,
we investigated whether NOTCH1 signaling could support the
expression of activated STAT3 that is observed in SS. However,
using short-term culturing systems, we could not demonstrate
cooperation of NOTCH1 and STAT3 signaling in SS.
In addition to T-ALL, dysregulated expression of NOTCH-
1 has been found in myeloma, colon cancer, breast cancer,
pancreas cancer, and melanoma (Ranganathan et al., 2011),
and various treatments are being developed to inhibit
NOTCH signaling. The most extensively studied target is
gamma-secretase, which can be inhibited effectively by GSI
treatment. Clinical trials with GSI are now performed in T-
cell leukemias, multiple myeloma, melanoma, pancreas
carcinoma, breast carcinoma, lung carcinoma, prostate
carcinoma, and glioblastoma. To investigate whether inhibi-
tion of NOTCH induces apoptosis of SS cells and conse-
quently might serve as a therapeutic target in this disease, we
performed short-term cultures of SS cells with GSI-I and GSI-
XXI. We found that inhibition of NOTCH1 induces apoptosis
of Se´zary cells, in a manner similar to that demonstrated for
other hematological malignancies such as T-ALL, myeloma,
and solid cancers including glioblastoma, breast cancer, and
colon carcinoma cells. The GSIs included in this study (GSI-I
and GSI-XXI) show considerable differences in efficacy in the
inhibition of NOTCH signaling and induction of apoptosis
(Figure 3). These results are in line with previous reported
differential effects of GSIs in other malignancies including
Kaposi’s sarcoma, cutaneous lymphomas, and breast cancer
(Curry et al., 2005; Rizzo et al., 2008; Kamstrup et al., 2010).
Although we clearly demonstrate that treatment of Se´zary
cells with GSI-I results in reduced icNOTCH1 expression and
subsequent increased apoptosis, off-target effects of GSI-I on
Se´zary cells cannot be excluded and remain to be elucidated.
In summary, we demonstrate that NOTCH1 and its
canonical target gene HES-1 are expressed by Se´zary cells.
We found no mutations in the NOTCH1 and the FBWX7
gene that could underpin the icNOTCH1 expression and
demonstrate that inhibition of NOTCH1 signaling leads to
induction of apoptosis of Se´zary cells. Together, these data
indicate that inhibition of NOTCH1 signaling might offer a
promising therapeutic target for SS.
MATERIALS AND METHODS
Patient selection
Sixteen patients with SS (nine men and seven women; median age of
64 years) were diagnosed based on criteria of the WHO/EORTC
2005 classification (Willemze et al., 2005). All patients presented
with erythroderma, and showed T-cell clonality in the peripheral
blood, increased CD4 counts with a CD4/CD8 ratio of 410 (mean
30, range 11–245). Follow-up data revealed that seven patients had
died of SS after a median follow-up of 44 months (Supplementary
Table S2 online). As controls, patients with psoriasis (n¼ 6) and
atopic dermatitis (n¼ 8) were included.
Approval for these studies was obtained from the Leiden
University Medical Center review board, and written informed
consent was provided according to the Declaration of Helsinki
Principles.
Immunohistochemistry
Serial sections of 4 mm were blocked for endogenous peroxidase
with 1% H2O2 in 100% methanol for 30minutes. Antigen retrieval
was performed with 10mM monocitric acid (pH 6.0) at 100 1C for
15minutes. The slides were blocked with nonimmune serum for
20minutes at room temperature. The sections were stained using the
primary antibodies against cleaved NOTCH1 (anti-NOTCH1, 1:75;
Cell Signaling Technology, Boston MA) and HES1 (anti-HES1, 1:100;
Santa Cruz Biotechnology, Santa Cruz, CA). Binding of the primary
antibody was visualized by the addition of Envision (horseradish
peroxidase-labeled mouse antibody, undiluted; DAKO, Glostrup,
Denmark). Normal, healthy human colon was used as control.
Cell culturing and stimulation
SeAx, a cell line derived from the peripheral blood of a patient with
SS (kindly provided by Dr K Kaltoft) (Kaltoft et al., 1987), was
cultured in RPMI-1640 (Invitrogen, Breda, The Netherlands),
supplemented with 10% fetal calf serum (HyClone/Greiner, Nu¨rtin-
gen, Germany), 2mM L-glutamine (Invitrogen), 100 IUml1 penicil-
lin, 100mgml1 streptomycin (Invitrogen), and 200Uml1 IL-2
(PeproTech, Rocky Hill, NJ). HuT78, a cell line derived from
peripheral blood of a patient with SS (ATCC number TIB-161), was
cultured in RPMI-1640 supplemented with 10% fetal calf serum,
2mM L-glutamine, 100Uml1 penicillin, and 100 mgml1 strepto-
mycin. Heparinized blood was drawn from patients and peripheral
blood mononuclear cells were isolated by Ficoll density centrifuga-
tion. Subsequently, CD4þ T cells were isolated by negative
selection with magnetic beads (CD4þ T-cell isolation kit, Miltenyi
Biotec, Bergisch Gladbach, Germany). The purity of the cell
population was determined by flow cytometry for CD3, CD4, and
CD8 expression, and was generally 485%. In addition, earlier
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experiments demonstrated that 490% of the CD4þ cells comprise
malignant cells characterized by expression of a clonally rearranged
T-cell receptor. The freshly isolated CD4þ T cells were maintained
in RPMI 1640 medium supplemented with 10% human AB serum
(Greiner Bio-One, Alphen aan den Rijn, The Netherlands), 2mM L-
glutamine, 100Uml–1 penicillin, 100mgml–1 streptomycin,
200Uml–1 IL-2, and 5 ngml–1 IL-7 (PeproTech).
Cells were incubated with GSI-XXI (Compound E, Alexa
Biochemicals, San Diego, CA), GSI-I (Calbiochem, San Diego,
CA), in the concentrations indicated, 40 mM JAG1 peptide (AnaSpec,
Freemont, CA), or 100 ngml–1 IL-21 (ImmunoTools, Friesoythe,
Germany).
Analysis of cell survival and apoptosis
To measure cell survival after inhibition of NOTCH1 signaling,
primary SS cells or SeAx were incubated with GSI in the
concentrations indicated in a 96-wells plate (six wells per condition).
After 72 hours, cell proliferation reagent WST-1 (Roche, Mannheim,
Germany) was added, and absorbance at 450 nm and 650 nm
(reference wavelength) was measured after 8 hours. The number of
viable cells was calculated relative to the numbers of nontreated
cells.
Apoptosis was evaluated by staining cells with FITC-conjugated
antibodies against Annexin-V (ImmnunoTools, Friesoythe, Germany)
and propidium iodide according to the manufacturer’s recommen-
dation. Samples were acquired on a flow cytometer (FacsCalibur,
BD Biosciences, Franklin Lakes, NY) and analyzed using the
CellQuest software (BD Biosciences).
Flow cytometry
STAT3 activation was measured by flow cytometry. Cells were
activated, fixed, and stained using Alexa647-conjugated antibodies
against phosphorylated STAT3 (BD Bioscience), as described
previously (van der Fits et al. 2011).
To measure the levels of icNOTCH1, cells were permeabilized
using BD lyse solution (BD Biosciences) and stained with phycoer-
ythrin-conjugated anti-icNOTCH1 (Abcam, Cambridge, UK) or
phycoerythrin-conjugated mouse IgG (Abcam) for 30minutes at 4 1C
in the dark. Samples were acquired on a flow cytometer (FacsCalibur,
BD Biosciences) and analyzed using the CellQuest software (BD
Biosciences).
Mutation analysis
Genomic DNA and total RNA were obtained from the CD4þ T cells
isolated from peripheral blood of 10 SS patients using DNeasy and
RNeasy (Qiagen, Hilden, Germany), respectively. Two mg isolated
RNA from each patient was subjected to DNAse treatment (RQ1,
Bio-Rad, Hemel Hempstead, UK) before complementary DNA
synthesis (IScript Kit, Bio-Rad). The coding region of each gene
was amplified by PCR using a series of overlapping primers. The PCR
primer sets (Beacon Designer, premier Biosoft, Palo Alto, CA)
typically generate PCR products between 500 and 1,000 bp, under
typical 40 thermal cycles (95 1C/20 s; 60 1C/15 s; 72 1C/50 s). The
specificity of PCR products was verified by melting curve analysis
(My IQ, Bio-Rad) before purification (MinElute 96UF, Qiagen). The
purified PCR fragments were sequenced both with forward and
reverse primers (ABI 3700, Applied Biosystems, Foster City, CA). The
sequenced PCR fragments of each gene were aligned and then
referred to the corresponding normal sequences (Ensembl database).
The nucleotide alterations of each gene were analyzed using a
software (Mutation Explorer, Softgenetic, State College, PA) based on
the consensus of sequencing results of forward and reverse
sequencing. Finally, the identified nucleotide alterations were
blasted against NCBI SNP database.
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